BioNTech SE (BNTX) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
BNTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
BNTX Revenue Analysis (2017–2024)
As of March 1, 2026, BioNTech SE (BNTX) generated trailing twelve-month (TTM) revenue of $3.15 billion, reflecting exceptional growth of +22.0% year-over-year. The most recent quarter (Q3 2025) recorded $1.52 billion in revenue, up 482.4% sequentially.
Looking at the longer-term picture, BNTX's 5-year compound annual growth rate (CAGR) stands at +90.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $18.98 billion in 2021.
Revenue diversification analysis shows BNTX's business is primarily driven by Other Sales (100%). With over half of revenue concentrated in Other Sales, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MRNA (-56.1% YoY), CDTX (-100.0% YoY), and SCNI (+303.9% YoY), BNTX has underperformed the peer group in terms of revenue growth. Compare BNTX vs MRNA →
Peer Comparison
Compare BNTX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BNTXCurrent | $3.2B | +22.0% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% | |
| VIR | $69M | -7.6% | +0.4% | -682.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $2.75B | -28.0% | $2.21B | 80.3% | $-1,314,300,000 | -47.8% |
| 2023 | $3.82B | -77.9% | $3.22B | 84.3% | $690.4M | 18.1% |
| 2022 | $17.31B | -8.8% | $14.32B | 82.7% | $12.64B | 73.0% |
| 2021 | $18.98B | +3834.6% | $16.07B | 84.7% | $15.28B | 80.5% |
| 2020 | $482.3M | +344.1% | $423.0M | 87.7% | $-82,400,000 | -17.1% |
| 2019 | $108.6M | -14.9% | $91.2M | 84.0% | $-181,500,000 | -167.1% |
| 2018 | $127.6M | +107.1% | $113.9M | 89.3% | $-53,854,000 | -42.2% |
| 2017 | $61.6M | - | $52.3M | 84.9% | $-61,277,000 | -99.5% |
See BNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BNTX vs AGIO
See how BNTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BNTX's revenue growth accelerating or slowing?
BNTX revenue is accelerating at +22.0% year-over-year, exceeding the 5-year CAGR of +90.9%. TTM revenue reached $3.2B. Growth momentum has increased versus prior periods.
What is BNTX's long-term revenue growth rate?
BioNTech SE's 5-year revenue CAGR of +90.9% reflects the sustained expansion pattern. Current YoY growth of +22.0% is above this long-term average.
How is BNTX's revenue distributed by segment?
BNTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.